CNBC’s Herb Greenberg warned investors several months ago that Intuitive Surgical wasn’t as good it appeared to be. Today, Greenberg was proven right.
CNBC’s Herb Greenberg warned investors several months ago that Intuitive Surgical wasn’t as good it appeared to be. Today, Greenberg was proven right. And Jim Cramer, Greenberg’s colleague on CNBC, tweeted this morning:
“Congratz to @HerbGreenberg for keeping the red flags flying on $ISRG”
Intuitive Surgical shares fell $87 today – more than 17% – after saying second quarter will be a disappointment. The maker of da Vinci surgical systems, which allows surgeons to remotely operate on patients, is forecasting revenues of $575 million, far less than the Wall Street’s estimates of $630 million.
Sales of its $1.5 million robotic surgical products fell 6% compared to last year, leading Goldman Sachs and Canaccord Genuity to both downgrade the company. Just two weeks ago, Canaccord rated the company a buy with a $527 price target. Shares are now trading at $415.
Airing on CNBC.com in April 2013, Greenberg’s investigative report (“The Da Vinci Debate”) looked at claims da Vinci machines potentially cause problems, particularly in benign gynecological surgeries. Such procedures are about half of all uses for da Vinci machines.
So does Greenberg see more pain to come, and what do the charts say?
Watch the video above to hear what Greenberg thinks will be next and to see Enis Taner, Global Macro Editor at RiskReversal.com, analyze the company's charts.
- Health Care Industry
- Intuitive Surgical
- Herb Greenberg